Akebia Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 09/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | — |
| Cost of revenue | $39.5M | $63.2M | $74.1M | $85.6M | — |
| Selling, general & administrative | $107.5M | $106.5M | $100.2M | $138.6M | — |
| Research and development | $62.4M | $37.7M | $63.1M | $130.0M | — |
| Operating expenses | $173.2M | $147.5M | $166.7M | $287.7M | — |
| Operating income | $23.5M | -$50.5M | -$46.3M | -$80.8M | — |
| Pretax income | -$3.7M | -$69.4M | -$51.9M | -$94.2M | — |
| Income tax expense | $1.6M | $0 | $0 | $0 | — |
| Net income | -$5.3M | -$69.4M | -$51.9M | -$94.2M | — |
| Balance Sheet | |||||
| Cash and equivalents | $184.8M | $51.9M | $42.9M | $90.5M | — |
| Current assets | $253.0M | $113.8M | $118.1M | $185.2M | $242.2M |
| Total assets | $376.6M | $220.7M | $241.7M | $356.1M | $444.3M |
| Current liabilities | $162.9M | $80.9M | $99.9M | $129.5M | $193.1M |
| Total liabilities | $344.0M | $269.9M | $272.3M | $350.8M | $436.0M |
| Total debt | $52.4M | $43.0M | $35.0M | $67.0M | — |
| Stockholders' equity | $32.6M | -$49.2M | -$30.6M | $5.2M | — |
| Cash Flow Statement | |||||
| Cash from operations | $68.0M | -$40.7M | -$23.4M | -$73.2M | — |
| Depreciation and amortization | $1.3M | $1.5M | $1.6M | $1.7M | — |
| Stock-based compensation | $11.3M | $7.8M | $9.3M | $17.8M | — |
| Capital expenditure | $291,000 | $33,000 | $0 | $114,000 | — |
| Free cash flow | $67.7M | -$40.7M | -$23.4M | -$73.3M | — |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 268.3M · Free float 93.6%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.